Inpatient Rsv-Management 2016-2022: Epidemiology and Adherence to A Bronchiolitis Treatment Standard at a German University Children’s Hospital.

Publication date: Feb 06, 2024

This study analyzes the RSV season 2021/2022 in a referral children’s hospital, compares the epidemiology and illness severity with RSV-infected inpatients from 2016 to 2020 and audits the adherence to our internal therapy standard for RSV bronchiolitis. Inpatients with rtPCR-confirmed RSV infection (Jan. 2016 to Jan. 2022). The audit comprises 306 RSV inpatients, on average 50 hospitalizations per year; in 03/2020, a rapid RSV Season-Offset was observed. In the winter season 2020/2021, no patient with RSV was hospitalized. Beginning in July, we noticed a rapid increase of RSV-admissions (most cases in Sept. /Oct, duration until Dec. 2021; n=53). In 2021-2022, a significant larger share needed PICU admission (9. 4% vs 3. 2%, p=0. 040). Adherence to the internal guidance was low; only 11. 8% (n=36) of all patients received supportive treatment without inhalative or systemic medications, 37% of all patients received antibiotics. This audit confirms the strong impact of public preventive measures directed against SARS-CoV-2 transmission on RSV epidemiology. Few weeks after easing public COVID-19 restrictions (summer 2021), RSV inpatient cases rapidly increased, lasting until Dec. 2021. The audit of bronchiolitis management revealed surprisingly low adherence to the internal guidance, despite a face-to-face educational session with the attending pediatricians in Oct. 2021. Low adherence resulted in an unnecessary exposure of RSV patients to systemic medications of questionable benefit including antibiotics.

Concepts Keywords
German Adherence
Hospitalizations Audit
July Bronchiolitis
Rapidly Children


Type Source Name
disease MESH Bronchiolitis
disease MESH infection
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)